Continuous antiretroviral therapy decreases bone mineral density. - Wikidata - awgldk - TriplyDB

Continuous antiretroviral therapy decreases bone mineral density.

Continuous antiretroviral therapy decreases bone mineral density.

http://www.wikidata.org/entity/Q37357149

about

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs HIV infection and osteoporosis Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial A cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 study Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial HIV infection and bone disease.Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence Incident fractures in HIV-infected individuals: a systematic review and meta-analysis Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.Increased risk of fragility fractures among HIV infected compared to uninfected male veterans.Prospective study of bone mineral density changes in aging men with or at risk for HIV infection.Bone mineral density in children and adolescents with perinatal HIV infection Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects.Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study.Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone loss.Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.Bone disease in HIV infection.Fracture risk by HIV infection status in perinatally HIV-exposed children.Fatal cumulative toxicities of HAART in a stable, AIDS-free, HIV-infected patient.Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required.Nucleosides accelerate inflammatory osteolysis, acting as distinct innate immune activators.Bone loss in HIV: a contemporary review.HIV and its effects on bone: a primer for rheumatologists Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: women's interagency HIV study.HIV status is an independent risk factor for reporting lower urinary tract symptoms.HIV and bone metabolism HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture.Fractures after antiretroviral initiation.Trabecular and cortical microarchitecture in postmenopausal HIV-infected women.Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy Bone health in children and adolescents with perinatal HIV infection Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: comparison with dual X-ray absorptiometry

P2860

Q26781795-6BBCF96F-4F4D-459D-82C2-FD833CCB3D32 Q26853139-D35217CA-C611-49CD-910F-81D94F7BE582 Q27030828-D345D3EE-8D48-4AB2-87E8-A3D2089A6FEA Q28468387-815E33E1-6B3E-4672-B4C2-6BEDEA6F28B8 Q28477736-2BFC3172-0C64-4839-9152-7887482740FC Q28483723-E8367F90-981C-4C02-B5D6-41E706A35317 Q28534700-ED29AD56-CBE2-4FCF-8176-D9A86AC0D676 Q28730855-CF9E1112-C395-41A7-8864-BD9A3CC75225 Q30249771-302D2552-4A5D-40A3-B281-0DE1C9240019 Q33627227-F4859A4B-E71C-471A-BEFB-E62CAF3B7EC1 Q33648297-556CBF19-E285-4B03-9697-5EEAB67572A8 Q33665210-6D57A913-553C-4511-BF66-69411DF65CFD Q33832012-79336501-017A-43CA-B6A0-6A1DB1BD34F1 Q34116648-0C5EFF49-5E75-4F15-BFA0-06BEACD6A145 Q34150394-33DF3ED9-94D9-47F2-B329-F79870243820 Q34264297-624C0F6F-E6F1-4E02-B55A-7BFDF82FAF8A Q34380767-58D4416E-A3A9-45F4-9917-46EFC8DB46DE Q35024409-19D59EA2-A348-4B2A-B3AA-2B5650768689 Q35025528-93D7D514-277C-4968-BCF2-03FB7514B405 Q35040559-D08FB58C-8DD8-4985-B048-2E6AC57FFDB9 Q35102114-439696B8-9738-4377-B314-BAC92DBBE704 Q35291766-96781C94-C4E0-4CB6-8F15-F60DF7529EF1 Q35557338-A91BFF26-2029-41BD-9FB5-C60C0A610DEA Q35593296-C14E9503-D685-4768-A83D-F9D8742AA80B Q35799101-212F1229-5729-43EF-B887-95EA272805B2 Q35863590-EA19BEDE-AB70-4622-A9FB-E834FA1338E3 Q36019580-755EB576-1F78-458F-A856-9EDCC9E552B1 Q36033710-11F10AC5-AFDE-42AF-8F10-46107AF20567 Q36257329-B8827415-5332-4728-AAAA-08CBC43463F3 Q36330955-BB8B4E6F-E8E4-4480-8F8F-5A094B8B4864 Q36381079-71439FB3-4A19-40DA-9B45-1E31C70B7BB4 Q36389108-A24A6502-1AF0-4455-A95F-E7E70DF5E8B5 Q36590841-F66C5A8A-7D12-4A0A-B22B-6DF21C0D9207 Q36671233-4EA793F9-30D9-477C-9CE8-F18E63BD09C3 Q36783435-8EDCCF31-58F8-4876-B865-88A9C8E5F461 Q36839748-267512BA-AB2A-42F8-8C40-61062D04B45A Q36849920-CF138F36-7D7A-4763-9F56-47B4FE1BA56B Q36853309-D0457F6F-72AE-45A0-A1F7-31302E27BD0A Q36941678-70ACE584-98ED-4591-84E9-0BEAD095D54C Q36981208-43527BA4-34E5-4349-9B2D-3A95107CD95D

P2860

Continuous antiretroviral therapy decreases bone mineral density.

http://www.wikidata.org/entity/Q37357149

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Continuous antiretroviral therapy decreases bone mineral density.

@en

Continuous antiretroviral therapy decreases bone mineral density.

@nl

type

label

Continuous antiretroviral therapy decreases bone mineral density.

@en

Continuous antiretroviral therapy decreases bone mineral density.

@nl

prefLabel

Continuous antiretroviral therapy decreases bone mineral density.

@en

Continuous antiretroviral therapy decreases bone mineral density.

@nl

P1433

Q37357149-4F290D6F-C509-410A-96B2-B7CBF88171A0

P1476

Q37357149-E3E525B0-E3FE-4D53-9DA1-7B2C8CD53388

P2093

Q37357149-18885F29-7FCA-4330-BAF0-1432E59B030E

Q37357149-308AEAAF-3F1B-4B82-972D-2A7933FE6514

Q37357149-3EBB5444-425E-4DDC-BA04-CDEA551A2FC6

Q37357149-8E13159D-9477-4ADC-8D2A-845F48DDC511

Q37357149-9AA688D6-9DA8-4602-8E34-34CDE678135C

Q37357149-A94C8091-A94A-4ECF-859E-813F9824AD20

Q37357149-BAB07C84-8345-46C8-B5FB-1F37BEBB5577

Q37357149-C1D13179-A861-460C-92E3-19416EAC7220

Q37357149-D6C57733-563F-4896-B0E1-B1B94D033C12

Q37357149-F605E4D9-8319-4353-8121-46B9E12F865E

P2860

Q37357149-01110F7C-787E-40BC-AE01-53CF82E87ED1

Q37357149-07B5A497-728F-4DFA-9C18-2747BAEF2D24

Q37357149-0A7C5CE9-8D20-4797-98AB-32446C5E5A6B

Q37357149-125A2812-C9CD-4286-BAB0-D181961A5C06

Q37357149-14574625-22E0-47E9-92A4-368761C1EFE3

Q37357149-14B17C38-706B-4883-8DBB-65DF4DD59989

Q37357149-14CDA586-1F46-4FC9-857B-89C9E0741197

Q37357149-151C2B38-2203-4E32-B0CA-D564A9830693

Q37357149-2302A397-52D3-40BF-A093-A391D70BD2EA

Q37357149-2E6ACAF5-9AA2-412A-B18F-CE5B880B9CEA

P304

Q37357149-26D8D34C-B69B-41F1-8592-7AC3CDE7F603

P31

Q37357149-6C975E8E-FE04-4F9B-A0E0-141CD1984187

P356

Q37357149-D65769FC-FE75-40F2-A7D4-3FE344164600

P407

Q37357149-B08898AA-E50E-4DF6-932D-E57AE4BE0F47

P433

Q37357149-B38EF6CC-3CAD-42A0-9712-8EBA8A0DDCF4

P478

Q37357149-42A695C9-ABF5-4917-999D-D6B469C22BDE

P577

Q37357149-683BAED8-A80D-4215-BC61-19DBBD7ECAA3

P698

Q37357149-DA51539C-8ACE-48B7-A208-D1BD4D141F3B

P921

Q37357149-9A408F28-CE6F-4393-99C1-5CDA2F90B42A

P932

Q37357149-8E6D909D-D5FB-42A3-AC7B-A2BFA41969B0

P356

QAD.0B013E32832C1792

P1433

P1476

Continuous antiretroviral therapy decreases bone mineral density.

@en

P2093

Andrew D Carr

http://www.w3.org/2001/XMLSchema#string

Birgit Grund

http://www.w3.org/2001/XMLSchema#string

Cynthia L Gibert

http://www.w3.org/2001/XMLSchema#string

Esteban Martinez

http://www.w3.org/2001/XMLSchema#string

Fehmida Visnegarwala

http://www.w3.org/2001/XMLSchema#string

Grace Peng

http://www.w3.org/2001/XMLSchema#string

INSIGHT SMART Body Composition Substudy Group

http://www.w3.org/2001/XMLSchema#string

Jennifer F Hoy

http://www.w3.org/2001/XMLSchema#string

Judith C Shlay

http://www.w3.org/2001/XMLSchema#string

Peter Reiss

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

CD4+ count-guided interruption of antiretroviral treatment

Updated data on proximal femur bone mineral levels of US adults.

Diagnosis of osteoporosis and assessment of fracture risk.

Bone mass and mineral metabolism in HIV+ postmenopausal women.

Longitudinal analysis of bone density in human immunodeficiency virus-infected women

Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection

Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.

Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification.

P304

1519-1529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32832C1792

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19531929

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2748675

http://www.w3.org/2001/XMLSchema#string